STAT6 siRNA matrix-loaded gelatin nanocarriers: Formulation, characterization, and Ex vivo proof of concept using adenocarcinoma cells

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Youngren, Susanne R ^a   Tekade, Rakesh K ^a   Gustilo, Brianne ^a   Hoffmann, Peter R ^b   Chougule, Mahavir B ^a  

^a UNIVERSITY OF HAWAII AT HILO   (United States)

^b UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BUFFER; GELATIN; LIPOFECTAMINE; NANOCARRIER; PLACEBO; SMALL INTERFERING RNA; STAT6 PROTEIN; NANOCAPSULE; STAT6 PROTEIN, HUMAN;

AGAR GEL ELECTROPHORESIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG ANALYSIS; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG STABILITY; ELECTROPHORETIC MOBILITY; EX VIVO STUDY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG ADENOCARCINOMA; NANOENCAPSULATION; PARTICLE SIZE; PH; SURFACE CHARGE; SUSTAINED DRUG RELEASE; ADENOCARCINOMA; CELL SURVIVAL; CHEMISTRY; DRUG ANTAGONISM; GENE TRANSFER; GENETICS; LUNG TUMOR; MEDICINAL CHEMISTRY; MOLECULAR WEIGHT; NANOMEDICINE; PATHOLOGY; RNA STABILITY; TUMOR CELL LINE;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; GELATIN; GENE TRANSFER TECHNIQUES; HUMANS; LUNG NEOPLASMS; MOLECULAR WEIGHT; NANOCAPSULES; NANOMEDICINE; PARTICLE SIZE; RNA STABILITY; RNA, SMALL INTERFERING; STAT6 TRANSCRIPTION FACTOR;

EID: 84885605439     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/858946     Document Type: Article

References (100)

1. Bagasra O., Prilliman K. R., RNA interference: the molecular immune system. Journal of Molecular Histology 2004 35 6 545 553 2-s2.0-16644398282 10.1007/s10735-004-2192-8 (Pubitemid 41404640)
2. Rana T. M., Illuminating the silence: understanding the structure and function of small RNAs. Nature Reviews Molecular Cell Biology 2007 8 1 23 36 2-s2.0-33845755467 10.1038/nrm2085 (Pubitemid 46012012)
3. Ali H. M., Urbinati G., Raouane M., Massaad-Massade L., Significance and applications of nanoparticles in siRNA delivery for cancer therapy. Expert Review of Clinical Pharmacology 2012 5 403 412
4. Tomkinson A., Kanehiro A., Rabinovitch N., Joetham A., Cieslewicz G., Gelfand E. W., The failure of STAT6-deficient mice to develop airway eosinophilia and airway hyperresponsiveness is overcome by interleukin-5. American Journal of Respiratory and Critical Care Medicine 1999 160 4 1283 1291 2-s2.0-0032828226 (Pubitemid 29487472)
5. Nelms K., Keegan A. D., Zamorano J., Ryan J. J., Paul W. E., The IL-4 receptor: signaling mechanisms and biologic functions. Annual Review of Immunology 1999 17 701 738 2-s2.0-0033010373 10.1146/annurev.immunol.17.1.701 (Pubitemid 29241138)
6. Woetmann A., Brockdorff J., Lovato P., Nielsen M., Leick V., Rieneck K., Svejgaard A., Geisler C., Ødum N., Protein phosphatase 2A (PP2A) regulates interleukin-4-mediated STAT6 signaling. The Journal of Biological Chemistry 2003 278 5 2787 2791 2-s2.0-0037474264 10.1074/jbc.M210196200 (Pubitemid 36801180)
7. Kato A., Yoshidome H., Edwards M. J., Lentsch A. B., Reduced hepatic ischemia/reperfusion injury by IL-4: potential anti-inflammatory role of STAT6. Inflammation Research 2000 49 6 275 279 2-s2.0-0033936394 10.1007/s000110050592 (Pubitemid 30451610)
8. Iff J., Wang W., Sajic T., Oudry N., Gueneau E., Hopfgartner G., Varesio E., Szanto I., Differential proteomic analysis of STAT6 knockout mice reveals new regulatory function in liver lipid homeostasis. Journal of Proteome Research 2009 8 10 4511 4524 2-s2.0-70349976548 10.1021/pr9003272
9. Zhang M., Zhou Y., Xie C., Zhou F., Chen Y., Han G., Zhang W. J., STAT6 specific shRNA inhibits proliferation and induces apoptosis in colon cancer HT-29 cells. Cancer Letters 2006 243 1 38 46 2-s2.0-33749234543 10.1016/j.canlet.2005.11.020 (Pubitemid 44485318)
10. Das S., Roth C. P., Wasson L. M., Vishwanatha J. K., Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Prostate 2007 67 14 1550 1564 2-s2.0-35148822215 10.1002/pros.20640 (Pubitemid 47536154)
11. Cui X., Zhang L., Luo J., Rajasekaran A., Hazra S., Cacalano N., Dubinett S. M., Unphosphorylated STAT6 contributes to constitutive cyclooxygenase-2 expression in human non-small cell lung cancer. Oncogene 2007 26 29 4253 4260 2-s2.0-34250858021 10.1038/sj.onc.1210222 (Pubitemid 46975804)
12. Cui X. Y., Yang S. C., Dalwadi H., Sharma S., Cacalano N., Dubinett S., STAT6 mediates IL-4 inhibition of cyclooxygenase-2 (COX-2): defining native regulation of COX-2 to develop new targets for lung cancer chemoprevention. Cancer Epidemiology Biomarkers & Prevention 2004 13 1879S 1880S
13. Dubey R., Chhabra R., Saini N., Small interfering RNA against transcription factor STAT6 leads to increased cholesterol synthesis in lung cancer cell lines. PLoS ONE 2011 6 12 2-s2.0-82655180427 10.1371/journal.pone. 0028509 e28509
14. Aoudjehane L., Podevin P., Scatton O., Jaffray P., Dusanter-Fourt I., Feldmann G., Massault P., Grira L., Bringuier A., Dousset B., Chouzenoux S., Soubrane O., Calmus Y., Conti F., Interleukin-4 induces human hepatocyte apoptosis through a Fas-independent pathway. The FASEB Journal 2007 21 7 1433 1444 2-s2.0-34247637682 10.1096/fj.06-6319com (Pubitemid 46684846)
15. Martin N., Innes J. A., Lambert C. M., Turnbull C. M., Wallace W. A. H., Hypersensitivity pneumonitis associated with leflunomide therapy. Journal of Rheumatology 2007 34 9 1934 1937 2-s2.0-35948953881 (Pubitemid 350067658)
16. Cortes J. R., Perez-G M., Rivas M. D., Zamorano J., Kaempferol inhibits IL-4-induced STAT6 activation by specifically targeting JAK3. Journal of Immunology 2007 179 6 3881 3887 2-s2.0-35748973566
17. Glebova K. V., Marakhonov A. V., Baranova A. V., Skoblov M. I., Therapeutic siRNAs and non-viral systems for their delivery. Molekuliarnaia Biologiia 2012 46 371 386
18. Tekade R. K., Dutta T., Tyagi A., Bharti A. C., Das B. C., Jain N. K., Surface-engineered dendrimers for dual drug delivery: a receptor up-regulation and enhanced cancer targeting strategy. Journal of Drug Targeting 2008 16 10 758 772 2-s2.0-56349134979 10.1080/10611860802473154
19. Kayat J., Gajbhiye V., Tekade R. K., Jain N. K., Pulmonary toxicity of carbon nanotubes: a systematic report. Nanomedicine 2011 7 1 40 49 2-s2.0-78751703392 10.1016/j.nano.2010.06.008
20. 2 receptor antagonist. European Journal of Medicinal Chemistry 2009 44 3 1155 1166 2-s2.0-60549108884 10.1016/j.ejmech.2008.06.012
21. Dwivedi P., Tekade R. K., Jain N. K., Nanoparticulate carrier mediated intranasal delivery of insulin for the restoration of memory signaling in Alzheimer's disease. Current Nanoscience 2013 9 46 55
22. Kurmi B. D., Kayat J., Gajbhiye V., Tekade R. K., Jain N. K., Micro- and nanocarrier-mediated lung targeting. Expert Opinion on Drug Delivery 2010 7 7 781 794 2-s2.0-77953862482 10.1517/17425247.2010.492212
23. Tekade R. K., Dutta T., Gajbhiye V., Jain N. K., Exploring dendrimer towards dual drug delivery: PH responsive simultaneous drug-release kinetics. Journal of Microencapsulation 2009 26 4 287 296 2-s2.0-70350404331 10.1080/02652040802312572
24. Kesharwani P., Gajbhiye V., Tekade R. K., Jain N. K., Evaluation of dendrimer safety and efficacy through cell line studies. Current Drug Targets 2011 12 10 1478 1497 2-s2.0-80051675175 10.2174/138945011796818135
25. Maheshwari R. G. S., Tekade R. K., Dharvekar G., Jain D. K., Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: a comparative assessment. Saudi Pharmaceutical Journal 2012 20 2 161 170 2-s2.0-84860343371 10.1016/j.jsps.2011.10.001
26. Benfer M., Kissel T., Cellular uptake mechanism and knockdown activity of siRNA-loaded biodegradable DEAPA-PVA-g-PLGA nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 2012 80 2 247 256 2-s2.0-84856599417 10.1016/j.ejpb.2011.10.021
27. Kaul G., Amiji M., Biodistribution and targeting potential of poly(ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model. Journal of Drug Targeting 2004 12 9-10 585 591 2-s2.0-11944266278 10.1080/10611860400013451 (Pubitemid 40100706)
28. Yang S. Y., Zheng Y., Chen J. Y., Comprehensive study of cationic liposomes composed of DC-Chol and cholesterol with different mole ratios for gene transfection. Colloids and Surfaces B 2012 101 6 13. 2012 Elsevier B.V
29. Thakur S., Tekade R. K., Kesharwani P., Jain N. K., The effect of polyethylene glycol spacer chain length on the tumor targeting potential of folate modified PPI dendrimers. Journal of Nanoparticle Research 2013 15 1625
30. Tekade R. K., Kumar P. V., Jain N. K., Dendrimers in oncology: an expanding horizon. Chemical Reviews 2009 109 1 49 87 2-s2.0-59649120675 10.1021/cr068212n
31. Jain N. K., Tekade R. K., Dendrimers for enhanced drug solubilization. Drug Delivery Strategies for Poorly Water-Soluble Drugs 2013 New York, NY, USA John Wiley & Sons 373 409
32. Gajbhiye V., Palanirajan V. K., Tekade R. K., Jain N. K., Dendrimers as therapeutic agents: a systematic review. Journal of Pharmacy and Pharmacology 2009 61 8 989 1003 2-s2.0-70249113729 10.1211/jpp/61.08.0002
33. Prajapati R. N., Tekade R. K., Gupta U., Gajbhiye V., Jain N. K., Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. Molecular Pharmaceutics 2009 6 3 940 950 2-s2.0-67249135321 10.1021/mp8002489
34. Kesharwani P., Tekade R. K., Gajbhiye V., Jain K., Jain N. K., Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomedicine 2011 7 3 295 304 2-s2.0-79956340892 10.1016/j.nano.2010.10.010
35. Dhakad R. S., Tekade R. K., Jain N. K., Cancer targeting potential of folate targeted nanocarrier under comparative influence of tretinoin and dexamethasone. Current Drug Delivery 2013 10 4 477 491
36. Coester C., Nayyar P., Samuel J., In vitro uptake of gelatin nanoparticles by murine dendritic cells and their intracellular localisation. European Journal of Pharmaceutics and Biopharmaceutics 2006 62 3 306 314 2-s2.0-33644826104 10.1016/j.ejpb.2005.09.009 (Pubitemid 43356580)
37. Coester C. J., Langer K., von Briesen H., Kreuter J., Gelatin nanoparticles by two step desolvation-a new preparation method, surface modifications and cell uptake. Journal of Microencapsulation 2000 17 2 187 193 2-s2.0-0034092776 (Pubitemid 30135796)
38. Balthasar S., Michaelis K., Dinauer N., von Briesen H., Kreuter J., Langer K., Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials 2005 26 15 2723 2732 2-s2.0-10044279371 10.1016/j.biomaterials.2004.07.047 (Pubitemid 39600725)
39. Lee E. J., Khan S. A., Park J. K., Lim K., Studies on the characteristics of drug-loaded gelatin nanoparticles prepared by nanoprecipitation. Bioprocess and Biosystems Engineering 2012 35 1-2 297 307 2-s2.0-84857454742 10.1007/s00449-011-0591-2
40. Azarmi S., Huang Y., Chen H., McQuarrie S., Abrams D., Roa W., Finlay W. H., Miller G. G., Löbenberg R., Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells. Journal of Pharmacy and Pharmaceutical Sciences 2006 9 1 124 132 2-s2.0-33645036467
41. Ichite N., Chougule M., Patel A. R., Jackson T., Safe S., Singh M., Inhalation delivery of a novel diindolylmethane derivative for the treatment of lung cancer. Molecular Cancer Therapeutics 2010 9 11 3003 3014 2-s2.0-78649653633 10.1158/1535-7163.MCT-09-1104
42. Chougule M., Padhi B., Misra A., Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics. International Journal of Nanomedicine 2007 2 675 688
43. Patlolla R. R., Chougule M., Patel A. R., Jackson T., Tata P. N. V., Singh M., Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. Journal of Controlled Release 2010 144 2 233 241 2-s2.0-77952670687 10.1016/j.jconrel.2010.02.006
44. Langer K., Balthasar S., Vogel V., Dinauer N., von Briesen H., Schubert D., Optimization of the preparation process for human serum albumin (HSA) nanoparticles. International Journal of Pharmaceutics 2003 257 1-2 169 180 2-s2.0-0037433794 10.1016/S0378-5173(03)00134-0 (Pubitemid 36507043)
45. Kriegel C., Amiji M., Oral TNF- α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. Journal of Controlled Release 2011 150 1 77 86 2-s2.0-79951955176 10.1016/j.jconrel.2010.10.002
46. Reif R., Haque F., Guo P., Fluorogenic RNA nanoparticles for monitoring RNA folding and degradation in real time in living cells. Nucleic Acid Therapeutics 2012 22 428 437
47. Kennedy S., Wang D., Ruvkun G., A conserved siRNA-degrading RNase negatively regulates RNA interference in C. elegans. Nature 2004 427 6975 645 649 2-s2.0-1342346710 10.1038/nature02302 (Pubitemid 38248485)
48. Ichite N., Chougule M. B., Jackson T., Fulzele S. V., Safe S., Singh M., Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clinical Cancer Research 2009 15 2 543 552 2-s2.0-59449101323 10.1158/1078-0432.CCR-08-1558
49. Youngren S., Mulik R., Jun B., Hoffmann P., Morris K., Chougule M., Freeze-dried targeted mannosylated seleniumloaded nanoliposomes: development and evaluation. AAPS PharmSciTech. In press
50. Darcan-Nicolaisen Y., Meinicke H., Fels G., Hegend O., Haberland A., Kühl A., Loddenkemper C., Witzenrath M., Kube S., Henke W., Hamelmann E., Small interfering RNA against transcription factor STAT6 inhibits allergic airway inflammation and hyperreactivity in mice 1. Journal of Immunology 2009 182 12 7501 7508 2-s2.0-67649232613 10.4049/jimmunol.0713433
51. + T cells in mice through a mechanism involving cellular free thiols. Journal of Nutrition 2010 140 6 1155 1161 2-s2.0-77952609172 10.3945/jn.109.120725
52. Society A. C., Cancer Facts & Figures 2013 2013 Atlanta, Ga, USA American Cancer Soceity
53. Sterman D. H., Kaiser L. R., Albelda S. M., Advances in the treatment of malignant pleural mesothelioma. Chest 1999 116 2 504 520 2-s2.0-0032782922 10.1378/chest.116.2.504 (Pubitemid 29382138)
54. Chougule M., Patel A. R., Sachdeva P., Jackson T., Singh M., Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer. Lung Cancer 2011 71 3 271 282 2-s2.0-79851512201 10.1016/j.lungcan.2010.06.002
55. Saffari M., Shirazi F. H., Oghabian M. A., Moghimi H. R., Preparation and in-vitro evaluation of an antisense-containing cationic Liposome against non-small cell lung cancer: a comparative preparation study. Iranian Journal of Pharmaceutical Research 2013 12 1 8
56. Remon J., Lianes P., Martinez S., Velasco M., Querol R., Zanui M., Malignant mesothelioma: new insights into a rare disease. Cancer Treatment Reviews 2013 39 6 584 591
57. Jänne P. A., Wozniak A. J., Belani C. P., Keohan M., Ross H. J., Polikoff J. A., Mintzer D. M., Ye Z., Monberg M. J., Obasaju C. K., Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. Journal of Thoracic Oncology 2006 1 506 512 (Pubitemid 47181396)
58. Kommareddy S., Amiji M. M., Protein nanospheres for gene delivery. Cold Spring Harbor Protocols 2008 10.1101/pdb.top30 (Pubitemid 351802481)
59. Xu J., Ganesh S., Amiji M., Non-condensing polymeric nanoparticles for targeted gene and siRNA delivery. International Journal of Pharmaceutics 2012 427 1 21 34 2-s2.0-84858747359 10.1016/j.ijpharm.2011.05.036
60. Won Y., Yoon S., Sonn C. H., Lee K., Kim Y., Nano self-assembly of recombinant human gelatin conjugated with α -tocopheryl succinate for Hsp90 inhibitor, 17-AAG, delivery. ACS Nano 2011 5 5 3839 3848 2-s2.0-80051497797 10.1021/nn200173u
61. Keenan T. R., Moeller M., Matyjaszewski K., Gelatin. Polymer Science: A Comprehensive Reference 2012 10 Amsterdam, The Netherland Elsevier BV 237 247
62. Zwiorek K., Bourquin C., Battiany J., Winter G., Endres S., Hartmann G., Coester C., Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharmaceutical Research 2008 25 3 551 562 2-s2.0-40549096768 10.1007/s11095-007-9410-5 (Pubitemid 351357729)
63. Kushibiki T., Tomoshige R., Fukunaka Y., Kakemi M., Tabata Y., In vivo release and gene expression of plasmid DNA by hydrogels of gelatin with different cationization extents. Journal of Controlled Release 2003 90 2 207 216 2-s2.0-0038179220 10.1016/S0168-3659(03)00197-4 (Pubitemid 36694964)
64. Obata Y., Nishino T., Kushibiki T., Tomoshige R., Xia Z., Miyazaki M., Abe K., Koji T., Tabata Y., Kohno S., HSP47 siRNA conjugated with cationized gelatin microspheres suppresses peritoneal fibrosis in mice. Acta Biomaterialia 2012 8 2688 2696 2-s2.0-84859918774 10.1016/j.actbio.2012.03.050
65. Kadengodlu P. A., Aigaki T., Abe H., Ito Y., Cationic cholesterol-modified gelatin as an in vitro siRNA delivery vehicle. Molecular BioSystems 2013 9 965 968
66. Kommareddy S., Amiji M., Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione. Bioconjugate Chemistry 2005 16 6 1423 1432 2-s2.0-27944507339 10.1021/bc050146t (Pubitemid 41681508)
67. Lemieux P., Guérin N., Paradis G., Proulx R., Chistyakova L., Kabanov A., Alakhov V., A combination of poloxamers increases gene expression of plasmid DNA in skeletal muscle. Gene Therapy 2000 7 11 986 991 2-s2.0-0034044578 (Pubitemid 30386664)
68. Bourquin C., Wurzenberger C., Heidegger S., Fuchs S., Anz D., Weigel S., Sandholzer N., Winter G., Coester C., Endres S., Delivery of immunostimulatory RNA oligonucleotides by gelatin nanoparticles triggers an efficient antitumoral response. Journal of Immunotherapy 2010 33 9 935 944 2-s2.0-78149281913 10.1097/CJI.0b013e3181f5dfa7
69. Saito T., Tabata Y., Preparation of gelatin hydrogels incorporating small interfering RNA for the controlled release. Journal of Drug Targeting 2012 20 864 872
70. Giraudier S., Hellio D., Djabourov M., Larreta-Garde V., Influence of weak and covalent bonds on formation and hydrolysis of gelatin networks. Biomacromolecules 2004 5 5 1662 1666 2-s2.0-5044241166 10.1021/bm049670d (Pubitemid 39341159)
71. Alameh M., DeJesus D., Jean M., Low molecular weight chitosan nanoparticulate system at low N: P ratio for nontoxic polynucleotide delivery. International Journal of Nanomedicine 2012 7 1399 1414
72. Taheri E. S., Jahanshahi M., Mosavian M. T. H., Preparation, characterization and optimization of egg albumin nanoparticles as low molecular-weight drug delivery vehicle. Particle & Particle Systems Characterization 2012 29 211 222
73. Braga D., Grepioni F., Maini L., Polito M., Crystal polymorphism and multiple crystal forms. Structure and Bonding 2009 132 25 50 2-s2.0-72049117097 10.1007/430-2008-7
74. Asghari I., Esmaeilzadeh F., Formation of ultrafine deferasirox particles via rapid expansion of supercritical solution (RESS process) using Taguchi approach. International Journal of Pharmaceutics 2012 433 149 156
75. Jahanshahia M., Sanati M. H., Babaeia Z., Optimization of parameters for the fabrication of gelatin nanoparticles by the Taguchi robust design method. Journal of Applied Statistics 2008 35 12 1345 1353 10.1080/02664760802382426
76. Severino P., Santana M. H. A., Souto E. B., Optimizing SLN and NLC by 22 full factorial design: effect of homogenization technique. Materials Science and Engineering C 2012 32 1375 1379 2-s2.0-84860568677 10.1016/j.msec.2012.04.017
77. Bhavsar M. D., Tiwari S. B., Amiji M. M., Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. Journal of Controlled Release 2006 110 2 422 430 2-s2.0-29244442282 10.1016/j.jconrel.2005.11.001 (Pubitemid 41827496)
78. Dillen K., Vandervoort J., van den Mooter G., Verheyden L., Ludwig A., Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles. International Journal of Pharmaceutics 2004 275 1-2 171 187 2-s2.0-1842789742 10.1016/j.ijpharm.2004.01.033 (Pubitemid 38481530)
79. Sarsambi K P. S. C., Rao K. P., Spectrophotometric estimation of gemcitabine in bulk drug and its formulation. IJPI's Journal of Analytical Chemistry 2011 1 18 24
80. Wadher S., Pathankar P., Puranik M., Ganjiwale R., Yeole P., Simultaneous spectrophotometric estimation of paracetamol and metoclopramide hydrochloride in solid dosage form. Indian Journal of Pharmaceutical Sciences 2008 70 3 393 395 2-s2.0-52149112982 10.4103/0250-474X.43014
81. Dastmalchi S., Rashidi M. R., Rassi M., Simultaneous determination of the pKa and octanol/water partition coefficient (Pm) of acetaminophen. Journal of School of Pharmacy, Medical Sciences University of Tehran 1995 4 7 14
82. Rahimnejad M., Jahanshahi M., Najafpour G. D., Production of biological nanoparticles from bovine serum albumin for drug delivery. African Journal of Biotechnology 2006 5 20 1918 1923 2-s2.0-33750965495 (Pubitemid 44736967)
83. Maeda H., Nakamura H., Fang J., The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Advanced Drug Delivery Reviews 2013 65 71 79
84. Kreuter J., Peroral administration of nanoparticles. Advanced Drug Delivery Reviews 1991 7 1 71 86 2-s2.0-0026186291 10.1016/0169-409X(91)90048-H
85. Khan S. A., Schneider M., Improvement of nanoprecipitation technique for preparation of gelatin nanoparticles and potential macromolecular drug loading. Macromolecular Bioscience 2013 13 455 463
86. Chougule M. B., Padhi B. K., Misra A., Nano-liposomal dry powder inhaler of amiloride hydrochloride. Journal of Nanoscience and Nanotechnology 2006 6 9-10 3001 3009 2-s2.0-33750068603 10.1166/jnn.2006.405 (Pubitemid 44579975)
87. Gan Q., Wang T., Chitosan nanoparticle as protein delivery carrier-systematic examination of fabrication conditions for efficient loading and release. Colloids and Surfaces B 2007 59 1 24 34 2-s2.0-34347324085 10.1016/j.colsurfb.2007.04.009 (Pubitemid 47016920)
88. Hao Z., Qu B., Wang Y., Tang S., Wang G., Qiu M., Zhang R., Liu Y., Xiao X., Preparation and characterization of lung-targeting ceftiofur-loaded gelatin microspheres. Drug Development and Industrial Pharmacy 2011 37 12 1422 1428 2-s2.0-80955135480 10.3109/03639045.2011.584192
89. Zaupa A., Neffe A. T., Pierce B. F., Nöchel U., Lendlein A., Influence of tyrosine-derived moieties and drying conditions on the formation of helices in gelatin. Biomacromolecules 2011 12 1 75 81 2-s2.0-78651307803 10.1021/bm101029k
90. Sundar S., Kundu J., Kundu S. C., Biopolymeric nanoparticles. Science and Technology of Advanced Materials 2010 11 014104 10.1088/1468-6996/11/1/014104
91. Karmali P. P., Simberg D., Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opinion on Drug Delivery 2011 8 3 343 357 2-s2.0-79951898882 10.1517/17425247.2011.554818
92. Shah S., Hypoxia in tumor angiogenesis and metastasis: evaluation of VEGFand MMP over-expression and down-regulation of HIF-1a with RNAi in hypoxic tumor cells [M.S. thesis] 2010 Boston, Mass, USA Northeastern University
93. Kaul G., Amiji M., Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharmaceutical Research 2002 19 7 1061 1067 2-s2.0-0035997341 10.1023/A:1016486910719 (Pubitemid 34804251)
94. Douglas K. L., Piccirillo C. A., Tabrizian M., Cell line-dependent internalization pathways and intracellular trafficking determine transfection efficiency of nanoparticle vectors. European Journal of Pharmaceutics and Biopharmaceutics 2008 68 3 676 687 2-s2.0-39849086966 10.1016/j.ejpb.2007.09.002 (Pubitemid 351318216)
95. Greenspan P., Mayer E. P., Fowler S. D., Nile red: a selective fluorescent stain for intracellular lipid droplets. Journal of Cell Biology 1985 100 3 965 973 2-s2.0-0021923858 (Pubitemid 15135357)
96. Greenspan P., Fowler S. D., Spectrofluorometric studies of the lipid probe, nile red. Journal of Lipid Research 1985 26 7 781 789 2-s2.0-0021816546 (Pubitemid 15046441)
97. Li B. H., Xu S. B., Li F., Zou X. G., Saimaiti A., Simayi D., Wang Y. H., Zhang Y., Yuan J., Zhang W. J., Stat6 activity-related Th2 cytokine profile and tumor growth advantage of human colorectal cancer cells in vitro and in vivo. Cellular Signalling 2012 24 3 718 725 2-s2.0-84855603600 10.1016/j.cellsig.2011. 11.005
98. Wurster A. L., Tanaka T., Grusby M. J., The biology of Stat4 and Stat6. Oncogene 2000 19 21 2577 2584 2-s2.0-0034658501 (Pubitemid 30339213)
99. Baus D., Nonnenmacher F., Jankowski S., Döring C., Bräutigam C., Frank M., Hansmann M.-L., Pfitzner E., STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line. Leukemia 2009 23 10 1885 1893 2-s2.0-70350123881 10.1038/leu.2009.103
100. Kriegel C., Attarwala H., Amiji M., Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract. Advanced Drug Delivery Reviews 2013 65 6 891 901